Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK42360 in BRAF V600-mutated solid tumors
NCT06536400Phase 1Recruiting
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Jun 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HSK42360 in solid tumor (3 arms), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoints: Maximum Tolerated Dose, Dose-Limiting Toxicities and 4 more. Started Jun 2024; status: recruiting.
02
Drugs
HSK42360
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06536400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06536400.